Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic systemic inflammatory diseases and share pathogenic pathways like the TNFα pathway.
Introduction
Results (II)
Patients and Methods
The aim of this study is to understand how systemic inflammation determines the pathological consequences that cause bone resorption and erosion in RA and bone formation in AS. Our hypothesis is that there are differences in osteoclast differentiation pathways between AS and RA.
Results (I)
We found that RANKL T and B lymphocyte expression was significantly higher in AS and RA patients when compared to healthy donors (p=0.0445 and 0.0016, respectively). We also found a positive correlation between RANKL expression in T cells and HAQ index in RA patients (p<0.01, Spearman r=0.9341 , data not shown).
Frequency of both classical (CD14 bright CD16 negative ) and non-classical (CD14 dim CD16 positive ) was increased in AS and RA patients when compared to healthy donors (p<0.0001 and p=0.0227, respectively; data not shown).
We also found that in the classical subpopulation RANK expression was lower in AS patients as compared to healthy controls (p=0.0073; Fig.2A ). Moreover, in the intermediate subpopulation this decrease was also found when comparing AS and RA patients (p=0.0203, Fig.2B ).
Discussion
AS patients: -do not differ from controls with regards to RANKL surface expression ; -have less RANK expression at the surface of osteoclast precursors; -have reduced markers of both bone formation and bone resorption;
In conclusion, despite comparable osteoclastogenic stimuli between AS and RA patients, RANK expression is reduced in AS circulating monocytes which may contribute to the bone forming phenotype observed in AS patients.
Rheumatoid Arthritis (RA) Ankylosing Spondylitis (AS)
• Joint inflammation originates in the synovial membrane of peripheral joints
• Bone and joint destruction
• Primary site of inflammation located at the enthesis or at the subchondral bone marrow • Bony spurs formation (syndesmophytes) Data are represented as mean±standard deviation unless stated otherwise; *p-value<0.05 is considered significant; RArheumatoid arthritis; AS -ankylosing spondylitis; NSAIDs -non-steroidal anti-inflammatory drugs; ESR -erythrocyte sedimentation rate; CRP -C-reactive protein; DAS -disease activity score; HAQ -health assessment questionnaire; RFrheumatoid factor; ACPA -anti-citrullinated protein antibody; BASDAI -Bath ankylosing spondylitis disease activity index; ASDAS -ankylosing spondylitis disease activity score; BASFI -Bath ankylosing spondylitis functional index ; nc -not comparable 
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When analyzing the circulating levels of cytokines in AS we found that there were no differences when compared to healthy controls. When comparing to RA we found that cytokines related to B and T cell activation (like IL-1β, IL-4 and IL-6) and cytokines from the IL-17 axis, namely IL-12 (p70) and IL-17, were significantly lower in AS when compared to RA (data not shown). No differences were found regarding sRANKL, OPG, sRANKL/OPG ratio or DKK-1 levels between groups (data not shown).
Regarding circulating bone turnover markers we detected that CTX-I and P1NP serum levels were also lower in AS patients than in healthy controls (p=0.0100 and p=0.0195, respectively; Fig 3) . 
